Idiopathic Pulmonary Fibrosis Therapeutics Market Analysis, Size, Development and Forecast to 2022

GLOBAL INDUSTRY INSIGHT: Idiopathic Pulmonary Fibrosis Therapeutics Market Analysis, Size, Share, Development, Growth and Demand Forecast to 2022

Idiopathic Pulmonary Fibrosis Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2022

The global idiopathic pulmonary fibrosis therapeutics market is expected to witness significant growth due to current unmet medical need of pulmonary fibrosis, scarcity of the permanent treatment of the disease, increasing incidence among population across the globe, and high demand for safe and effective medication. The regulatory bodies are supporting the idiopathic pulmonary fibrosis market by providing designations and grants for speeding up the drug development process. In March 2015, Lebrikizumab, a Genentech’s humanized monoclonal antibody drug, received Orphan Drug Designation by U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis.

Explore

Full

Report

Description

with

Detailed

TOC

at:

https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeuticsmarket The pipeline of idiopathic pulmonary fibrosis is rich, with more than 50 drugs. The pharmaceutical companies are actively involved in the research and development of drug for idiopathic pulmonary fibrosis. Asahi Kasei Pharma Corporation has Thrombomodulin Alfa drug in its Phase III clinical trial for idiopathic pulmonary fibrosis. The drug is already marketed in Japan, under the name of Recomodulin for the treatment of disseminated intravascular coagulation.

Idiopathic pulmonary fibrosis is defined as a chronic, gradually increasing lung disease of unknown cause. The disease primarily involves the interstitium (the tissue and space around the air sacs of the lungs) and it does not directly affect the airways or blood vessels. The lung damage caused by pulmonary fibrosis cannot be repaired; however, medications and therapies can help to ease symptoms and improve quality of life. Management and surgery are the only options to prevent further complications of idiopathic pulmonary fibrosis. The damage caused from the lung scarring cannot be reversed.

A large number of pharmaceutical companies are investing in research and development activities for idiopathic pulmonary fibrosis therapeutics. However, certain factors such as unknown etiology, complex pathophysiology and high treatment cost of idiopathic pulmonary fibrosis are expected to hamper the growth of global market during the forecast period.

Geographically, North America is expected to be the largest market for idiopathic pulmonary fibrosis owing to the large number of research and development activities, high healthcare

Š P&S Market Research. All rights reserved

2

Idiopathic Pulmonary Fibrosis Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2022

expenditure, and high incidence of the disease. The U.S. contributed largest revenue to the North American idiopathic pulmonary fibrosis market and it is expected to remain the largest market globally, during the forecast period.

Browse

Other

Related

Report

at:

https://www.psmarketresearch.com/industry-

report/healthcare Some of the key players operating in the global idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Merck & Co., Inc., Promedior, Inc., Sanofi, ProMetic Life Sciences Inc., Kadmon Holdings, Inc., MediciNova, Inc., GlaxoSmithKline plc, Biogen Inc., and Celgene Corporation.

About P&S Market Research P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact: Abhishek Executive – Client Partner 347, 5th Ave. #1402 New York City, NY - 10016 US/ Canada Toll-Free: 1-888-778-7886 Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com

Š P&S Market Research. All rights reserved

3